Biocon Biologics has announced the latest milestone in its integration of former partner Viatris’s biosimilars business, completing the move in the US and Canada “ahead of schedule.”
Biocon Biologics has taken the next step in integrating the biosimilars business of former partner Viatris into its operations, announcing that it has completed integration in the US and Canada “ahead of schedule” with effect from 1 September.
In early 2022, Biocon Biologics agreed to pay up to $3.3bn to acquire Viatris’s global biosimilars business. (Also see "
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
